AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17620371
Drug: Intermittent short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent short-term infusion of imipenem-cilastatin (1 g/1 g three times per day for 3 days, total daily dose 3 g/3 g)
Trial: 17620371
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Continuous and Intermittent infusion)
Trial: 15896431
Drug: Total daily
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total daily energy intake of REE x 1.7
Trial: 15896431
Drug: Total daily
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total daily energy intake of REE x 1.3
Trial: 12410192
Drug: Pamidronate (intravenous),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (intravenous), administered daily for 3 consecutive days, repeated at 3-month intervals for one year
Trial: 12410192
Drug: Placebo (plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (plain saline, intravenous), administered daily for 3 consecutive days, repeated at 3-month intervals for one year
Trial: 12410192
Drug: Pamidronate (intravenous)
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate (intravenous)
Trial: 12410192
Drug: Placebo (plain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (plain saline, intravenous)
Trial: 1924666
Drug: Fluphenazine hydrochloride
RxNorm normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine hydrochloride at 5 mg, 10 mg, or 20 mg daily for 4 weeks
Trial: 25754414
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro mix (mix 50 before breakfast and lunch plus mix 25 before dinner)
Trial: 25754414
Drug: Basal-bolus therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal-bolus therapy (insulin glargine at bedtime plus prandial insulin lispro thrice-daily)
Trial: 25754414
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin lispro mix
Trial: 14691621
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tramadol (intraarticular)
Trial: 14691621
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tramadol (intraarticular)
Trial: 14691621
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tramadol (intraarticular)
Trial: 14691621
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tramadol (intravenous)
Trial: 14691621
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tramadol (intravenous)
Trial: 14691621
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tramadol (intravenous)
Trial: 6741804
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (STK)
Trial: 31780038
Drug: Synbiotics (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synbiotics (500 mg capsule containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum plus inulin)
Trial: 22531205
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate administration (minimum 750 mg/d)
Trial: 22531205
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of sodium valproate administration
Trial: 19963274
Drug: Quetiapine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (average daily dose=232mg)
Trial: 15034229
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valerate 2 mg
Trial: 12941063
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three compounds (Climodien, Estradiol valerate, Placebo)
Trial: 8787364
Drug: Acellular diphtheria/pertussis/tetanus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular diphtheria/pertussis/tetanus (ADPT) vaccines
Trial: 8787364
Drug: Whole-cell diphtheria-pertussis-tetanus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-cell diphtheria-pertussis-tetanus (WCDPT) vaccine
Trial: 24555753
Drug: High-dose clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clarithromycin
Trial: 24555753
Drug: Low-dose clarithromycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose clarithromycin
Trial: 19482902
Drug: Ultrasound Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound Therapy (US)
Trial: 29164826
Drug: Jessner's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jessner's solution
Trial: 17136873
Drug: Loratadine plus
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine plus pseudoephedrine (L+P)
Trial: 11054327
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (group C)
Trial: 8627066
Drug: Proinflammatory cytokines
RxNorm normalized name: Arthriten Inflammatory Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proinflammatory cytokines (TNF-alpha, IL-6, IL-8) and counterinflammatory compounds (IL-10, sTNFR-55, sTNFR-75) levels
Trial: 8627066
Drug: Plasminogen activator
RxNorm normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasminogen activator inhibitor (PAI)-1 levels
Trial: 6588975
Drug: Clofibate 1
RxNorm normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofibate 1 g b.i.d.
Trial: 6588975
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid 3 g/day (b.i.d. or t.i.d.)
Trial: 6588975
Drug: Nicotinic acid
RxNorm normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinic acid 3.0 g/day (alternate to previous schedule) and gemfibrozil 1.2 g/d in divided doses
Trial: 31711464
Drug: Oral Polio
RxNorm normalized name: Oral Polio Vaccine
DrugBank: Oral Polio Vaccine (DB15864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Polio Vaccination (OPV)
Trial: 24708204
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) abatacept (125 mg weekly) with IV loading (∼10 mg/kg on Day 1)
Trial: 24708204
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) abatacept (∼10 mg/kg monthly)
Trial: 24708204
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) abatacept
Trial: 24708204
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) abatacept
Trial: 20426797
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 10 mg kg(‐1) day(‐1) for 30 days
Trial: 11871383
Drug: Plain-formulated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain-formulated aspirin (PF)
Trial: 11871383
Drug: Extended-release aspirin
RxNorm normalized name: aspirin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release aspirin (EX2)
Trial: 11871383
Drug: Extended-release aspirin
RxNorm normalized name: aspirin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release aspirin (EX5)
Trial: 11871383
Drug: Extended-release formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release formulations (EX2 and EX5)
Trial: 30659553
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral examination under white light
Trial: 28112412
Drug: Usual Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual Cognitive Stimulation Therapy control group
Trial: 25497262
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of eggs (breakfast with 2 eggs)
Trial: 22893555
Drug: Vinyl bags
RxNorm normalized name: vinyl neodecanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinyl bags (subgroup: birth weight <750 g)
Trial: 22893555
Drug: Thermal mattress
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal mattress (subgroup: birth weight <750 g)
Trial: 21059665
Drug: Ice therapy
RxNorm normalized name: Ice Therapy
DrugBank: Levomenthol (DB00825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ice therapy (repeated application of crushed ice)
Trial: 16542202
Drug: SLV317 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SLV317 (250 mg oral solution)
Trial: 15991587
Drug: Level II
RxNorm normalized name: BENZOYL PEROXIDE 50 mg in 1 mL TOPICAL GEL [DermaClear Purity Cleanser Level II]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level II (Intensive Outpatient Treatment)
Trial: 15991587
Drug: Level III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level III (Medically Monitored Residential Treatment)
Trial: 11104556
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent carboplatin (400 mg/m², administered on day 1 of a 21-day cycle for a total of 4 cycles)
Trial: 7693881
Drug: Staging laparotomy
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staging laparotomy plus treatment adaptation (adjuvant chemotherapy only in the 33% with negative laparotomy)
Trial: 27281813
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g fiber/d from SCF
Trial: 27281813
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g fiber/d from SCF
Trial: 27281813
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g fiber/d from SCF (Control)
Trial: 27281813
Drug: Calcium absorption
RxNorm normalized name: Evening Primrose Oil Oral Capsule, Liquid Filled [CALCIUM ABSORPTION FOR WOMEN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium absorption
Trial: 24698652
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac 0.1% drop, one drop 2h preoperatively and four times daily postoperatively for 3 days
Trial: 22161746
Drug: Multidisciplinary lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary lifestyle treatment (medical, nutritional, physical, and psychological counseling during 3 months)
Trial: 15265352
Drug: New drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New drugs and treatments for cancer pain management
Trial: 3068936
Drug: Heparin DHE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin DHE
Trial: 27038614
Drug: ACERTO protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACERTO protocol (n = 15): 6 h preoperative fasting for solids, oral drink (200 mL of 12.5% maltodextrin) up to 2 h before anesthesia, restricted intravenous fluids (1000 mL of crystalloid fluid after surgery), preoperative immune nutrition (600 mL/day of Impact - Nestlé, Brazil) for five days prior to surgery
Trial: 27038614
Drug: Traditional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional care (n = 17; control group): 6-8 h preoperative fasting, intravenous hydration until the 1st postoperative day, no preoperative immune supplementation
Trial: 10923604
Drug: Ketotifen, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen, 1 mg twice a day
Trial: 8736463
Drug: Nonresponders (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonresponders (no treatment specified)
Trial: 1349301
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg LHRH nasal spray three times daily for 4 weeks
Trial: 1349301
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg LHRH nasal spray
Trial: 8535553
Drug: Indomethacin 25
RxNorm normalized name: indomethacin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 25 mg three times daily
Trial: 30193810
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Conventional therapy for upper extremity for 60 minutes, 5 times per week for 4 weeks)
Trial: 3387508
Drug: Hypnotic suggestion
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnotic suggestion (Experiment 2)
Trial: 3387508
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Experiment 2)
Trial: 29049039
Drug: Blood samples
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood samples collected immediately after interrupting the medication from peripheral vein and CVC lines.
Trial: 29049039
Drug: Blood samples
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood samples collected 5 minutes after interrupting the infusion from peripheral vein and CVC lines.
Trial: 29049039
Drug: CVC line
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVC line used for infusion.
Trial: 23958147
Drug: Reduced high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced high-dose volume radiation therapy (RHDVRT)
Trial: 23958147
Drug: Standard whole-bladder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard whole-bladder radiation therapy (sRT)
Trial: 20542736
Drug: Methylprednisolone (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (500 mg/day orally for 3 consecutive days per month for 3-4 years)
Trial: 20542736
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical tablets to methylprednisolone)
Trial: 17705052
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (urokinase 12 h, urokinase 2 h, rtPA 50 mg, rtPA 100 mg) in group I
Trial: 17705052
Drug: Anticoagulants (heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants (heparin, nadroparin) in group II
Trial: 20586860
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg/day)
Trial: 12749247
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg/day) or Nizatidine (300 mg/day)
Trial: 12749247
Drug: No histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No histamine 2 receptor antagonists
Trial: 16335001
Drug: Canada split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canada split influenza virus vaccine (trial group)
Trial: 2282421
Drug: intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intermittent treatment (placebo)
Trial: 2282421
Drug: continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous treatment (control)
Trial: 7382709
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation therapy and surgery
Trial: 7382709
Drug: Surgery and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery and postoperative radiation therapy
Trial: 7382709
Drug: Surgery and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery and postoperative radiation therapy plus radical radiation therapy (for oral cavity and oropharynx lesions)
Trial: 26775385
Drug: Sedoanalgesia (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedoanalgesia (Group S): 1 mg/kg ketamine and 1 mg/kg propofol for induction, followed by infusion of 100-150 μg kg(‐1) min(‐1) propofol and 0.25 mg kg(‐1) h(‐1) ketamine for maintenance
Trial: 26775385
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (Group G): 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen for induction, maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen
Trial: 7919750
Drug: Formula supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula supplements
Trial: 28142160
Drug: Tiopronin 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiopronin 500 mg
Trial: 17234566
Drug: Craniosacral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craniosacral therapy
Trial: 17234566
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and craniosacral therapy
Trial: 17234566
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments from one practitioner
Trial: 15199091
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (MVAC: methotrexate, vinblastine, doxorubicin, and cisplatin)
Trial: 11978332
Drug: Amodiaquine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (10 mg/kg per day for 3 days) plus artesunate (4 mg/kg per day for 3 days)
Trial: 11978332
Drug: Amodiaquine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amodiaquine (10 mg/kg per day for 3 days) and placebo
Trial: 10176148
Drug: diacerein 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diacerein 100 mg/day plus standard osteoarthritic therapy for 6 months, followed by a 3-month monitoring period without diacerein
Trial: 10176148
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy alone for the entire 9-month period
Trial: 10176148
Drug: diacerein plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diacerein plus standard therapy
Trial: 10176148
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy alone
Trial: 10176148
Drug: standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard therapy group
Trial: 1688616
Drug: Hydrazine sulfate
RxNorm normalized name: Hydrazine Sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrazine sulfate (60 mg, three times daily)
Trial: 31484539
Drug: Treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm 1 (not specified in detail)
Trial: 31484539
Drug: Treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm 2 (not specified in detail)
Trial: 31484539
Drug: Treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm 3 (initial treatment with etanercept and methotrexate)
Trial: 31484539
Drug: Treatment to
RxNorm normalized name: Lice Treatment Topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment to target aimed at inactive disease (all arms)
Trial: 23749293
Drug: BG-12 (dimethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG-12 (dimethyl fumarate) 240 mg twice daily (BID)
Trial: 23797999
Drug: BG-12 (dimethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG-12 (dimethyl fumarate) 240 mg three times daily (TID)
Trial: 16917670
Drug: A‐V Impulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A‐V Impulse System applied for 2 hours daily for 5 postoperative days
Trial: 11422030
Drug: PTU 100
RxNorm normalized name: PTU 100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTU 100 mg three times daily
Trial: 11422030
Drug: PTU plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTU plus thyroxine 25 microg once daily
Trial: 9101342
Drug: Buspirone (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (7.5 mg)
Trial: 20657533
Drug: Topical silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical silver oxide ointment
Trial: 18981465
Drug: Cilengitide 500
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide 500 mg
Trial: 18981465
Drug: Cilengitide 2000
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide 2000 mg
Trial: 15467103
Drug: Cystoseira canariensis
RxNorm normalized name: Cystoseira tamariscifolia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cystoseira canariensis supplementation (1200 mg/d)
Trial: 7987780
Drug: Group behavioral-cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group behavioral-cognitive therapy